Press Releases

CQDM, Diazon and the Oncopole announce the creation of a prize of excellence for graduate students in cancer research in memory of Professor Gordon Shore

Montreal, November 19, 2018 – CQDM, Diazon and the Oncopole, in collaboration with Mitacs, are pleased to announce the creation of the Gordon Shore Prize to pay tribute to the remarkable accomplishments of Professor Shore in the field of cancer research. CQDM, Diazon, the Oncopole, in collaboration with Mitacs, will endow the newly founded Gordon Shore Prize with an initial contribution of $24,000 to support the first industrial research experience of an outstanding graduate student. Additional partners will be invited to join CQDM, Diazon and the Oncopole to increase the number of training opportunities supported by this prize.

Diazon Pharmaceutical’s anti-cancer agent DZ-2384 mechanism for high activity and low neurotoxicity published by McGill researchers in Science Translational Medicine

Montreal, QC, November 16th 2016 – Diazon Pharmaceuticals Inc. today announced the publication of a preclinical oncology study identifying the novel mechanism of action of its new synthetic diazonamide compound, DZ-2384, in Science Translational Medicine. The results show that a distinct mode of binding to a classic therapeutic site in tubulin translates into superior anti-tumor activity and safety, including lack of neurotoxicity, with pre-clinical proof of concept in a wide range of cancers including triplenegative breast cancer and pancreatic cancer.